Software firm LZ Lifescience says small drugmakers could increase their productivity by over 25% by accessing Manufacturing Execution Systems (MESs) traditionally restricted to Big Pharma firms
Nasdaq-bound Chinese biopharma BeiGene has chosen GE Healthcare’s Flexfactory platform for the monoclonal antibody (mAb) plant it is building in Suzhou.
Data falsification at API facilities is getting harder to spot say regulators who have called for more systems training and international collaboration.
Protea Biosciences has teamed up with Agilent Technologies to offer drugmakers mass spectrometry alternatives to UV detection in QA/QC of recombinant proteins.
Sanofi Pasteur says Mexican approval for Dengvaxia vindicates the ‘industrial risk’ it took when it invested €350m in a dengue fever vaccine plant in 2009.
A new single-use bioproduction plant will bring in annual revenues of $40m, says Avid Bioservices which is already eyeing up additional capacity to cope with contract manufacturing demand.
Aptuit plans to up tabletting and encapsulation capacity at sites in the UK and Italy less than a year after it increased API output at the same facilities.
Danaher has bought production line monitoring and coding tech firm Laetus to bolster its life science product ID offering ahead of a planned corporate split next year.
Increasing interest in human genome sequencing and editing is driving demand for oligonucleotides, says Integrated DNA Technologies (IDT) which is buying AITbiotech’s synthesis business in Singapore.
Niche technologies will differentiate CMOs looking for a slice of the steady oral dosage manufacturing industry, according to an industry report from ISR.
Clariant will build a CHF10m ($9.7m) moisture control device plant in Cuddalore, Tamil Nadu to cater for the branded and generic drugmakers operating in India.
New acquisition Sigma Aldrich will play a part in African growth plans in addition to giving it a presence in the preclinical services sector says Merck*.
As CMOs wait to see the short-term fallout of the Pfizer-Allergan deal, an M&A expert says contract manufacturing will follow the CRO industry in embracing strategic alliances and consolidation.
Restarting production at the former Ben Venue facility in Ohio will be a “significant task” says Xellia Pharmaceuticals which plans to invest after buying the site from Hikma.
US Customs and Border Protection (CBP) says the country of origin of Carlsbad Technology’s acyclovir is where the API is sourced, not the US where the tablets are made.
Juniper Pharmaceuticals has made a “significant capital investment” to expand its Xcelodose powder micro-dosing system to feed demand for Phase I study materials.
Dyadic has agreed to sell its enzyme-producing fungal expression system and the rest of its industrial technology business to DuPont for $75 million (€70 million).
Out-of-place softgel capsules have led to the suspension of manufacturing at a site in France, and Catalent says the problem is almost certainly due to malicious actions.
Specialised drugs made using flexible technologies are the future for Roche’s small molecule portfolio, the firm says as it restructures its production network.
More than one hundred women are suing a subsidiary of Irish manufacturer Endo International, claiming a packaging error caused their contraception to fail and result in unwanted pregnancies.
The UK biopharma industry is reporting difficulties finding manufacturing workers with the skills to make vaccines, biologics, and advanced therapy medicinal products (ATMP), according to ABPI.
AMRI attributed recent M&A activity to passing the $100m (€93m) quarterly sales milestone, reporting high double-digit growth across its API and small-scale manufacturing divisions.
